Filtered By:
Specialty: Drugs & Pharmacology
Condition: Thrombosis

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 546 results found since Jan 2013.

Biomarker assays for personalised stroke risk assessment in atrial fibrillation.
Authors: Hall A, Simpson RF, Mitchell AR Abstract Atrial fibrillation is a well-known independent risk factor for stroke yet there is no international consensus on guidelines regarding the introduction of anticoagulation in patients deemed at intermediate risk (e.g. CHA₂DS₂-VASc of 1). The evolution of cardiac biomarkers such as highly sensitive troponins and B-type natriuretic peptide as well as data on D-dimers, may offer incremental enhancements for personalised thromboembolism risk assessment. These markers provide prognostic data for risk of cardiovascular morbidities associated with atrial fibrillation an...
Source: Cardiovascular and Hematological Disorders Drug Targets - January 7, 2017 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Cell Death Mechanisms in Stroke and Novel Molecular and Cellular Treatment Options.
Abstract As a result of ischemia or hemorrhage, blood supply to neurons is disrupted which subsequently promotes a cascade of pathophysiological responses resulting in cell loss. Many mechanisms are involved solely or in combination in this disorder including excitotoxicity, mitochondrial death pathways, and the release of free radicals, protein misfolding, apoptosis, necrosis, autophagy and inflammation. Besides neuronal cell loss, damage to and loss of astrocytes as well as injury to white matter contributes also to cerebral injury. The core problem in stroke is the loss of neuronal cells which makes recovery di...
Source: Current Neuropharmacology - March 1, 2018 Category: Drugs & Pharmacology Authors: Sekerdag E, Solaroglu I, Gursoy-Ozdemir Y Tags: Curr Neuropharmacol Source Type: research

Targeted nano-delivery strategies for facilitating thrombolysis treatment in ischemic stroke.
This article begins with a brief introduction to ischemic stroke, then describes the current state of thrombolysis treatment and, finally, introduces the application of various nanotechnology-based strategies for targeted delivery of thrombolytic agents. Representative studies are reviewed according to diverse strategies and nano-formulations, with the aim of providing integrated and up-to-date information and to improve the development of thrombolysis treatment for stroke patients. PMID: 33517820 [PubMed - in process]
Source: Drug Delivery - February 3, 2021 Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research

Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India
Curr Vasc Pharmacol. 2021 Nov 9. doi: 10.2174/1570161119666211109122231. Online ahead of print.ABSTRACTStroke is the second most common cause of death worldwide. The rates of stroke are increasing in less affluent countries predominantly because of a high prevalence of modifiable risk factors. The Lipid Association of India (LAI) has provided a risk stratification algorithm for patients with ischaemic stroke and recommended low density lipoprotein cholesterol (LDL-C) goals for those in a very high risk group and extreme risk group (category A) of <50 mg/dl (1.3 mmol/l) while the LDL-C goal for extreme risk group (catego...
Source: Current Vascular Pharmacology - November 9, 2021 Category: Drugs & Pharmacology Authors: Raman Puri Vimal Mehta S S Iyengar Padma Srivastava Jamal Yusuf Akshaya Pradhan Jeyaraj Durai Pandian Vijay K Sharma P N Renjen A Muruganathan K Mugundhan A V Srinivasan Sadanand Shetty S N Narasingan Devaki R Nair Manish Bansal D Prabhakar Mukul Varma Vi Source Type: research

Investigational drugs for ischemic stroke: what's in the clinical development pipeline for acute phase and prevention?
Expert Opin Investig Drugs. 2022 Apr 29. doi: 10.1080/13543784.2022.2072725. Online ahead of print.ABSTRACTINTRODUCTION: Stroke is a leading cause of disability and mortality and its burden expected to increase. The only approved drug for acute ischemic stroke is the intravenous thrombolytic alteplase. The risk of bleeding complications is one of the reasons for the undertreatment of eligible patients. Numerous drugs are currently being developed to improve safety-efficacy.AREAS COVERED: We reviewed literature from January 1st, 2000, to 15th January 2022 for the development and testing of novel drugs with the aim of target...
Source: Expert Opinion on Investigational Drugs - April 29, 2022 Category: Drugs & Pharmacology Authors: Maria Giulia Mosconi Maurizio Paciaroni Walter Ageno Source Type: research